Jiangsu HengRui Medicine Co., Ltd.: Neoplasms trials

The registry lists 70 Neoplasms studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 21 are open to participants now and 0 have results posted.

Phase 1 62Phase 2 18Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant TumorsRecruitingNCT07073534Phase 1/2
• A Trial of SHR-3792 Injection in Patients With Advanced Solid TumorsRecruitingNCT06907628Phase 1
• A Study of SHR-9803 for Injection in Patients With Advanced Solid TumorsNot yet recruitingNCT06906731Phase 1/2
• A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid TumorsRecruitingNCT06895928Phase 2
• A Study of SHR-4375 in Subjects With Solid TumorsRecruitingNCT06764628Phase 1/2
• A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid TumorsNot yet recruitingNCT06704828Phase 2
• A Trial of SHR-A2102 for Treatment of Advanced Gynecological MalignancyRecruitingNCT06654440Phase 2
• A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant TumorsRecruitingNCT06643754Phase 1/2
• A Trial of SHR-4849 in Advanced Solid TumorsRecruitingNCT06443489Phase 1
• Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid TumorsRecruitingNCT06439589Phase 1/2
• Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant TumorsNot yet recruitingNCT06131216Phase 1
• An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid TumorsRecruitingNCT06094556Phase 1
• A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid TumorsNot yet recruitingNCT06092268Phase 1/2
• Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant TumorsRecruitingNCT06059508Phase 1
• A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.RecruitingNCT06015048Phase 1/2
• A Study of SHR-A1811 in Subjects With Gynaecologic OncologyRecruitingNCT05896020Phase 2
• Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant TumorsRecruitingNCT05851092Phase 1
• A Study of SHR-4602 in Subjects With Advanced Malignant Solid TumorsRecruitingNCT05819684Phase 1
• A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid TumorsRecruitingNCT05794477Phase 1/2
• A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.RecruitingNCT05735275Phase 1
• Study of HRS-1167 as Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT05473624Phase 1
• A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid TumorsWithdrawnNCT06560138Phase 1
• The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid TumorsCompletedNCT06381050Phase 1
• Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy SubjectsCompletedNCT06093945Phase 1
• Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid TumorsActive, not recruitingNCT05765032Phase 1/2
• Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy SubjectsCompletedNCT05661591Phase 1
• A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid TumorsCompletedNCT05594875Phase 1
• Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy SubjectsCompletedNCT05592262Phase 1
• A Study of HR19024 in Subjects With Advanced Solid TumorCompletedNCT05463432Phase 1
• The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid TumorsCompletedNCT05394818Phase 1
• A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of PatientsStatus unknownNCT05214976Phase 2
• A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of PatientsStatus unknownNCT05198817Phase 1
• A Study of SHR-A1921 for Injection in Subjects With Advanced Solid TumoursStatus unknownNCT05154604Phase 1
• A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant TumorsCompletedNCT05144061Phase 1
• A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid TumorsCompletedNCT05086848Phase 1
• A Study of Irinotecan Hydrochloride Liposome in Advanced Solid TumorsCompletedNCT05086822Phase 1
• A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced MalignanciesTerminatedNCT05048134Phase 1
• Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid TumorsCompletedNCT04856774Phase 1/2
• A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid TumorsTerminatedNCT04842630Phase 1
• A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsStatus unknownNCT04679038Phase 1/2
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor SubjectsCompletedNCT04457180Phase 1
• A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.CompletedNCT04428086Phase 1
• A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant TumoursCompletedNCT04414150Phase 1
• Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorCompletedNCT04346381Phase 2
• A Trial of SHR-1701 in Subjects With Advanced Solid TumorsCompletedNCT04324814Phase 1
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor SubjectsCompletedNCT04322552Phase 1
• A Study of SHR-1501 in Patients With Advanced TumorsCompletedNCT04025957Phase 1
• Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid TumorCompletedNCT04013048Phase 1
• A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced TumorsCompletedNCT03995472Phase 1
• A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid TumorsTerminatedNCT03871855Phase 1
• A Study of SHR-A1403 in Patients With Advanced Solid TumorCompletedNCT03856541Phase 1
• SHR-1701 in Subjects With Metastatic or Locally Advanced Solid TumorsStatus unknownNCT03774979Phase 1
• Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced MalignanciesSuspendedNCT03722186Phase 1
• SHR-1701 in Metastatic or Locally Advanced Solid TumorsStatus unknownNCT03710265Phase 1
• Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell NeoplasmstumorStatus unknownNCT03664297Phase 1
• Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid TumorsStatus unknownNCT03491631Phase 1
• Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid TumorsStatus unknownNCT03398720Phase 1
• A Trial of HTI-1090 in Subjects With Advanced Solid TumorsCompletedNCT03208959Phase 1
• The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsTerminatedNCT03182673Phase 1
• A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 3
• A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 2
• Phase I Study of SHR7390 in Patients With Advanced Solid TumorsStatus unknownNCT02968485Phase 1
• A Phase I Trial of SHR3162 in Subjects With Advanced Solid TumorsCompletedNCT02759666Phase 1
• A Phase I Trial of HS-10241 in Solid TumorsCompletedNCT02759640Phase 1
• A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor SubjectsCompletedNCT02721589Phase 1
• A Study of SHR6390 in Advanced Solid Tumor PatientsCompletedNCT02684266Phase 1
• A Phase I Study of Fluzoparib in Patient With Advanced Solid MalignanciesCompletedNCT02575651Phase 1
• Phase I Study of Pyrotinib in Patients With HER2-positive Solid TumorsStatus unknownNCT02500199Phase 1
• A Phase I Study of Famitinib Malate in Patients With Solid TumorCompletedNCT01762280Phase 1
• A Phase I Study of Henatinib in Patients With Advanced Solid MalignanciesTerminatedNCT01416623Phase 1